Agenda for October 2026 Cancer Treatments (CTAC) meeting

Information on what the Cancer Treatments Advisory Committee (CTAC) will be considering at its upcoming meeting in
October 2026. This has been rescheduled from September due to availability.

Tislelizumab (branded as TEVIMBRA) for gastric or gastro-oesophageal junction cancer

The Committee will discuss an application for tislelizumab for the treatment of people living with advanced or metastatic gastric or gastro-oesophageal junction cancer. The application is for first line treatment for people whose cancer is advanced or has spread, and the tumour is HER2-negative, and has a PD-L1 score of 5% or higher.

Tislelizumab (branded as TEVIMBRA) for oesophageal squamous cell cancer

The Committee will discuss tislelizumab for the treatment of people living with advanced or metastatic oesophageal squamous cell cancer. The application is for first line treatment for people whose cancer is advanced or has spread and whose tumour has a PD-L1 score of 1% or higher.

Pembrolizumab (branded as Keytruda) for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers

The Committee will discuss an application for pembrolizumab for people living with unresectable or metastatic cancers, with specific genetic features (known as MSI-H or dMMR), whose cancer has progressed despite previous treatment.